Astrazeneca (AZN) Long-Term Deferred Tax (2016 - 2026)

Astrazeneca has reported Long-Term Deferred Tax over the past 17 years, most recently at $5.6 billion for Q1 2026.

For Q1 2026, Long-Term Deferred Tax fell 8.24% year-over-year to $5.6 billion; the TTM value through Mar 2026 reached $5.6 billion, down 8.24%, while the annual FY2025 figure was $5.8 billion, 8.83% up from the prior year.
Long-Term Deferred Tax for Q1 2026 was $5.6 billion at Astrazeneca, down from $5.8 billion in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $6.3 billion in Q2 2025 and troughed at $3.3 billion in Q4 2022.
A 5-year average of $4.8 billion and a median of $4.7 billion in 2023 define the central range for Long-Term Deferred Tax.
On a YoY basis, Long-Term Deferred Tax climbed as much as 51.44% in 2022 and fell as far as 24.64% in 2022.
Year by year, Long-Term Deferred Tax stood at $3.3 billion in 2022, then soared by 44.59% to $4.7 billion in 2023, then rose by 13.33% to $5.3 billion in 2024, then increased by 8.83% to $5.8 billion in 2025, then fell by 3.88% to $5.6 billion in 2026.
Business Quant data shows Long-Term Deferred Tax for AZN at $5.6 billion in Q1 2026, $5.8 billion in Q4 2025, and $6.1 billion in Q3 2025.

Peer Comparison